350 IRAK4 drives pathogenic processes in inflammatory skin diseases

Abstract

In recent years innate immunity has moved into focus of therapeutically approaches due to its ability to drive downstream adaptive responses. Modulators of innate immune responses are expected to have high therapeutic potential across immune-mediated inflammatory diseases (IMIDs). The kinase IRAK4 integrates signaling downstream of receptors acting at the interface between innate and adaptive immune responses (e.g. TLRs, IL-1R, IL-18R). Here, we profiled a novel, selective IRAK4 inhibitor, GLPG2534, in an extensive series of in vitro, ex vivo, and in vivo models of inflammatory skin diseases (ISD).